PolarityTE (PTE) Receives a Buy from Northland Securities


In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on PolarityTE (PTE), with a price target of $20.00. The company’s shares closed last Monday at $2.91, close to its 52-week low of $2.10.

According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -14.8% and a 29.7% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.

Currently, the analyst consensus on PolarityTE is a Strong Buy with an average price target of $13.25, implying a 301.5% upside from current levels. In a report issued on November 11, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18.17 and a one-year low of $2.10. Currently, PolarityTE has an average volume of 323.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts